Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Merck
Express Scripts
Medtronic
Harvard Business School

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Lucitanib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Lucitanib?

Lucitanib is an investigational drug.

There have been 8 clinical trials for Lucitanib. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2014.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, and Neoplasms. The leading clinical trial sponsors are Clovis Oncology, Inc., Servier, and Bristol-Myers Squibb.

There are twelve US patents protecting this investigational drug and ninety-eight international patents.

Recent Clinical Trials for Lucitanib
TitleSponsorPhase
A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and ImmunotherapyBristol-Myers SquibbPhase 1/Phase 2
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorBristol-Myers SquibbPhase 1/Phase 2
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorClovis Oncology, Inc.Phase 1/Phase 2

See all Lucitanib clinical trials

Clinical Trial Summary for Lucitanib

Top disease conditions for Lucitanib
Top clinical trial sponsors for Lucitanib

See all Lucitanib clinical trials

US Patents for Lucitanib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lucitanib   Start Trial Human anti-VEGFR-2/KDR antibodies KADMON CORPORATION, LLC (New York, NY)   Start Trial
Lucitanib   Start Trial Rho kinase inhibitors KADMON CORPORATION, LLC (New York, NY)   Start Trial
Lucitanib   Start Trial Rho kinase inhibitors Kadmon Corporation, LLC (New York, NY)   Start Trial
Lucitanib   Start Trial Human anti-VEGFR-2/KDR antibodies Kadmon Corporation, LLC (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lucitanib

Drugname Country Document Number Estimated Expiration Related US Patent
Lucitanib Canada 2926386 2032-10-05   Start Trial
Lucitanib China 105007939 2032-10-05   Start Trial
Lucitanib China 109160950 2032-10-05   Start Trial
Lucitanib Eurasian Patent Organization 032679 2032-10-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Merck
Moodys
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.